These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11191654)

  • 1. Lymphangiogenesis and tumor metastasis: more questions than answers.
    Pepper MS
    Lymphology; 2000 Dec; 33(4):144-7. PubMed ID: 11191654
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticancer drug targets: approaching angiogenesis.
    Keshet E; Ben-Sasson SA
    J Clin Invest; 1999 Dec; 104(11):1497-501. PubMed ID: 10587512
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy.
    Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P
    Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084
    [No Abstract]   [Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.
    Jośko J; Gwóźdź B; Jedrzejowska-Szypułka H; Hendryk S
    Med Sci Monit; 2000; 6(5):1047-52. PubMed ID: 11208453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms and role of lymphangiogenesis in cancer metastasis].
    Dupuy E; Tobelem G
    Bull Cancer; 2003 Jul; 90(7):595-9. PubMed ID: 12957800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.
    Olaso E; Vidal-Vanaclocha F
    Methods Mol Med; 2003; 85():79-86. PubMed ID: 12710199
    [No Abstract]   [Full Text] [Related]  

  • 8. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review).
    Schoppmann SF; Horvat R; Birner P
    Oncol Rep; 2002; 9(3):455-60. PubMed ID: 11956609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
    Partanen TA; Paavonen K
    Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the use of angiogenesis inhibitors in cancer.
    Pinedo HM
    Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
    [No Abstract]   [Full Text] [Related]  

  • 11. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract]   [Full Text] [Related]  

  • 14. Vascular growth factors and lymphangiogenesis.
    Jussila L; Alitalo K
    Physiol Rev; 2002 Jul; 82(3):673-700. PubMed ID: 12087132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical implications of angiogenesis in the treatment of cancer.
    Aoun E; Taher A
    J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiogenesis, lymphangiogenesis, and tumor progression].
    Hawighorst T
    Zentralbl Gynakol; 2002 Nov; 124(11):497-505. PubMed ID: 12796842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
    Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma].
    Wu H; Li Y; Zhu G; Zhang L; Zhang X; He X
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(10):708-11. PubMed ID: 12133473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.